Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after... Original Atricle Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as  Prognostic Factors after Stereotactic Radiation Therapy for  Early-Stage Non–Small-Cell Lung Cancer Nathan A. Cannon, MD, PhD,* Jeffrey Meyer, MD,* Puneeth Iyengar, MD, PhD,* Chul Ahn, PhD,† Kenneth D. Westover, MD, PhD,* Hak Choy, MD,* and Robert Timmerman, MD* those patients where lobectomy is not an option, such as for Introduction: The hematologic indices of neutrophil-to-lymphocyte medically inoperable patients or for those unwilling to undergo ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are correlated surgery, stereotactic body radiation therapy, also known as with clinical outcomes after stereotactic radiation. stereotactic ablative radiotherapy (SABR), has shown efficacy Methods: We retrospectively evaluated the pretreatment NLR and with improved local control and survival outcomes relative to PLR in patients treated with stereotactic radiation for early stage traditional radiation therapy. non–small-cell lung cancer at our institution. A total of 149 patients The cellular components of the host hematologic sys- treated for non–small-cell lung cancer were identified, and 59 had tem, including cells involved in hemostasis, inflammation, and stage I disease with neutrophil, platelet, and lymphocyte levels within immunity, may influence survival outcomes in patients with a 3-month period before treatment. Receiver operating characteristic cancer. The neutrophil-to-lymphocyte ratio (NLR) is an easily (ROC) analysis was performed to examine cutoff values for survival derived http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Timmerman, Robert
Journal of Thoracic Oncology , Volume 10 (2) – Feb 1, 2015
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/neutrophil-ndash-lymphocyte-and-platelet-ndash-lymphocyte-ratios-as-sWBYll2yX3

References (34)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000399
pmid
25299234
Publisher site
See Article on Publisher Site

Abstract

Original Atricle Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as  Prognostic Factors after Stereotactic Radiation Therapy for  Early-Stage Non–Small-Cell Lung Cancer Nathan A. Cannon, MD, PhD,* Jeffrey Meyer, MD,* Puneeth Iyengar, MD, PhD,* Chul Ahn, PhD,† Kenneth D. Westover, MD, PhD,* Hak Choy, MD,* and Robert Timmerman, MD* those patients where lobectomy is not an option, such as for Introduction: The hematologic indices of neutrophil-to-lymphocyte medically inoperable patients or for those unwilling to undergo ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are correlated surgery, stereotactic body radiation therapy, also known as with clinical outcomes after stereotactic radiation. stereotactic ablative radiotherapy (SABR), has shown efficacy Methods: We retrospectively evaluated the pretreatment NLR and with improved local control and survival outcomes relative to PLR in patients treated with stereotactic radiation for early stage traditional radiation therapy. non–small-cell lung cancer at our institution. A total of 149 patients The cellular components of the host hematologic sys- treated for non–small-cell lung cancer were identified, and 59 had tem, including cells involved in hemostasis, inflammation, and stage I disease with neutrophil, platelet, and lymphocyte levels within immunity, may influence survival outcomes in patients with a 3-month period before treatment. Receiver operating characteristic cancer. The neutrophil-to-lymphocyte ratio (NLR) is an easily (ROC) analysis was performed to examine cutoff values for survival derived

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Feb 1, 2015

There are no references for this article.